Search / 96 results found

from
to
  • Updated

THURSDAY, Jan. 20, 2022 (HealthDay News) -- Recommendations have been updated for use of the recombinant zoster vaccine (RZV) for prevention of herpes zoster and related complications among immunocompromised adults aged 19 years and older; the recommendations are available in the Jan. 21 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

  • Updated

TUESDAY, Jan. 18, 2022 (HealthDay News) -- The U.S. Preventive Services Task Force (USPSTF) recommends that physicians individualize the decision to refer adults without known cardiovascular disease (CVD) risk factors to behavioral counseling interventions for healthy diet and physical activity. This recommendation forms the basis of a draft recommendation statement published by the USPSTF on Jan. 18.

  • Updated

TUESDAY, Jan. 18, 2022 (HealthDay News) -- Two sets of guidelines have been developed: one for the diagnosis and management of acute left-sided colonic diverticulitis and a second for the role of colonoscopy for diagnostic evaluation and interventions to prevent recurrence of acute left-sided colonic diverticulitis; the guidelines were published online Jan. 18 in the Annals of Internal Medicine.

  • Updated

FRIDAY, Jan. 14, 2022 (HealthDay News) -- The Janus kinase (JAK) inhibitor baricitinib is strongly recommended for patients with severe or critical COVID-19, and sotrovimab is conditionally recommended for nonsevere COVID-19, according to the updated World Health Organization living guideline on drugs for COVID-19, published online Jan. 13 in The BMJ.

  • Updated

FRIDAY, Jan. 14, 2022 (HealthDay News) -- The prevalence of colorectal neoplasia observed among younger outpatients undergoing colonoscopies supports the recommendation to lower the screening age for colorectal cancer (CRC) to age 45 years, according to a study published online Jan. 4 in Gastroenterology.

  • Updated

THURSDAY, Jan. 6, 2022 (HealthDay News) -- The U.S. Centers for Disease Control and Prevention on Wednesday endorsed the emergency use of the Pfizer booster shots for children ages 12 to 17 years, expanding protection to adolescents and teens as students return to classes and the highly contagious omicron variant surges across the country.